Acorda Therapeutics (ACOR) Shares are Down -23.46%

Acorda Therapeutics (ACOR) : During the past 4 weeks, traders have been relatively bearish on Acorda Therapeutics (ACOR), hence the stock is down -13.5% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -23.59% relative to the S&P 500. The 4-week change in the price of the stock is -13.97% and the stock has fallen -23.46% in the past 1 week.

The stock has recorded a 20-day Moving Average of 15.7% and the 50-Day Moving Average is 15.83%.The 200 Day SMA reached 29.42%


Acorda Therapeutics (NASDAQ:ACOR): After opening at $20.75, the stock dipped to an intraday low of $20.51 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $21.15 and the buying power remained strong till the end. The stock closed at $20.88 for the day, a gain of 1.16% for the day session. The total traded volume was 924,257. The stocks close on the previous trading day was $20.88.

Acorda Therapeutics (ACOR) : The highest short term price target forecast on Acorda Therapeutics (ACOR) is $60 and the lowest target price is $25. A total of 3 equity analysts are currently covering the company. The average price of all the analysts is $42.67 with a standard deviation of $17.5.

Acorda Therapeutics, Inc. is a biopharmaceutical company engaged in the identification, development and commercialization of therapies that restore neurological function and treat patients with neurological disorders. The Companys markets three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10milligrams, a treatment to improve walking in patients with multiple sclerosis (MS). It also markets Zanaflex Capsules and tablets, FDA-approved as short-acting drugs for the management of spasticity, and Qutenza, an FDA-approved dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia, also known as post-shingles pain. The Company is also developing a number of clinical and preclinical stage therapies for the treatment of a range of disorders, including chronic post-stroke walking deficits (PSWD), Parkinsons disease, epilepsy, heart failure, MS, and spinal cord injury.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.